🐦 推特Wall St EngineDoubao · 实盘不做把握 6/10不做原因:风险收益比不佳
北京时间·🕒 发布 04:06:34·⟳ 抓取 04:06:46 +12s·⚡ 决策 10-21 05:10:28 +1h03m·6.5 天前
直觉外科Q3营收、调整后EPS大幅超预期，但反垄断和解费用叠加偏保守指引，盘后一度跌约7%
表面大幅beat但净信息偏混合：4.5亿美元反垄断和解费用拖累GAAP利润、FY26毛利率指引68.7%-69.3%低于Q3的69.9%、手术量仅维持区间中段，盘后已被重定价至-7%(区间378-451美元)。做空是在一次性费用引发的急跌后追空、基本面(耗材+18%、放置+28%、29.4亿美元回购)并不支持持续下杀；做多则逆着明确的负面市场反应与保守指引接飞刀，多空风险收益比均不佳。
📄 原文Wall St Engine@wallstengine↗ 原文
INTUITIVE SURGICAL $ISRG Q3’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $3.05B (Est. $2.91B) 🟢; +22% YoY 🔹 Adj. EPS: $3.00 (Est.…
不做 Intuitive Surgical（ISRG.US）
典型beat但sell-the-news：盘后已跌约7%并在378-451美元间剧烈震荡，一次性和解费用+保守毛利率指引对空、强经常性增长+大额回购对多，两侧均无正期望；消息盘后放量已被大幅定价，等次日常规时段方向明朗后再评估
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
ISRG Q3调整后利润与收入大超预期、装机与手术量强劲，但反垄断一次性费用+毛利率指引低于本季+手术量指引未上修，触发典型sell-the-news，盘后-7%且剧烈震荡；消息已在盘后被实时大幅定价，方向与持续性均不明朗，回避。
消息传播链
- 公司官方发布Q3财报：营收30.5亿、调整后EPS 3.00双beat，同时披露4.5亿美元反垄断和解费用及偏保守FY26指引市场反应:盘后股价由收盘438美元下挫
- 媒体标题明确为'调整后盈利与营收增长但盘后股价下跌'，确认市场对指引/一次性费用作负面解读市场反应:盘后最低见378美元、最新约407美元(-6.98%)，区间振幅约19%
关键理由
- 做多角度：营收/EPS双beat、耗材复购+18%、系统放置+28%、29.4亿美元回购，经常性增长动能扎实
- 做空角度：毛利率指引低于本季、手术量指引维持中段未上修，且股价财报前处于近60日高位(20日+8.9%)，估值对指引容错低
主要风险
- 盘后378-451美元宽幅震荡说明多空分歧极大，次日常规时段方向未定，追空易遇一次性费用消化后的反弹，抄底易被指引下杀延续
- 若电话会重申达芬奇5放量或上修需求口径，-7%缺口可能快速回补；反之若毛利率压力被确认，跌势可能延续
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-20 · 影响 weakens
尽管大幅beat，盘后仍跌约7%，毛利率指引68.7%-69.3%低于Q3的69.9%且手术量指引未上修，市场明确负面
检索:ISRG Q3 2026 shares fall after hours guidance gross margin antitrust 原文 ↗ - 做空前查反向 · 来源 filing · 日期 2026-10-20 · 影响 weakens
GAAP EPS下滑主因一次性反垄断和解(税后0.99美元)，耗材+18%、放置+28%、Ion手术量+31%、季内回购29.4亿美元，无持续性盈利恶化
检索:Intuitive Surgical Q3 recurring growth instruments placements buyback one-time charge 原文 ↗
先例如何影响了这次决策
对本次决策的影响:不产出交易腿；先例缺失叠加盘后-7%既成事实，强化RISK_REWARD回避
方向:未调用历史先例面板：结论为回避(不涉及tp/sl幅度校准)，且当前盘后已出现极端宽幅定价，方向分歧本身足以否决多空两侧
涨幅量级:无高相似对齐先例；不据历史beat后反应定幅度
形态:2026年7月Q2财报亦出现'强劲季度仍吓退投资者'的类似标题，提示ISRG财报beat后盘后下杀并非孤例，但样本不足以支撑做空
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 14 ms
{"result": "search_processed_events:agent query=`intuitive surgical isrg q3 2026 earnings revenue eps beat antitrust settlement | 直觉外科 isrg 三季度财报 达芬奇 反垄断和解 指引`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - stock_quote 成功 stock_tools HTTP · 385 ms
{ - web_search 成功 doubao_search · 1,412 ms
豆包搜索结果（原始查询:Intuitive Surgical Q3 2026 earnings results revenue beat antitrust settlement guidance；API SearchType:web） - web_search 成功 doubao_search · 1,484 ms
豆包搜索结果（原始查询:ISRG Intuitive Surgical stock after hours Q3 2026 earnings reaction；API SearchType:web）
原文全文
展开原文 · 1,314 字
INTUITIVE SURGICAL $ISRG Q3’26 EARNINGS HIGHLIGHTS
🔹 Revenue: $3.05B (Est. $2.91B) 🟢; +22% YoY
🔹 Adj. EPS: $3.00 (Est. $2.64) 🟢; +25% YoY
🔹 GAAP EPS: $1.49; -24% YoY
🔹 Adj. Gross Margin: 69.9%
FY26 Guide:
🔹 da Vinci Procedure Growth: ~+14%-+15%
🔹 Adj. Gross Margin: 68.7%-69.3%
🔹 Adj. Opex Growth: +11%-+13%
Revenue Breakdown:
🔹 Instruments & Accessories: $1.80B; +18% YoY
🔹 Systems: $769M; +30% YoY
🔹 Services: $482.2M
Procedures:
🔹 Worldwide: ~+15% YoY
🔹 da Vinci: ~+14% YoY
🔹 Ion: ~+31% YoY
System Placements:
🔹 da Vinci: 546; +28% YoY
🔹 da Vinci 5: 315; +31% YoY
🔹 Ion: 56; +12% YoY
Other Q3 Metrics:
🔹 da Vinci Installed Base: 12,094; +12% YoY
🔹 Ion Installed Base: 1,152; +21% YoY
🔹 Adj. Oper Income: $1.27B (Est. $1.13B) 🟢
Key Updates:
🔹 Antitrust settlement charge: $450M; $347M net of tax, $0.99/share
🔹 IEEPA tariff refund benefit: $22M net of tax, $0.06/share; in GAAP and non-GAAP
🔹 Expects da Vinci procedure growth closer to the midpoint of the range
🔹 Share Repurchases: $2.94B; 7.8M shares
🔹 Cash, cash equivalents, and investments: $6.80B
Comments:
🔸 “Our strong performance this quarter was marked by broad-based adoption across our multi-port, single-port, and Ion platforms, with customers using our systems to perform, on average, over 10,000 procedures per day throughout the period.”
🔹 Revenue: $3.05B (Est. $2.91B) 🟢; +22% YoY
🔹 Adj. EPS: $3.00 (Est. $2.64) 🟢; +25% YoY
🔹 GAAP EPS: $1.49; -24% YoY
🔹 Adj. Gross Margin: 69.9%
FY26 Guide:
🔹 da Vinci Procedure Growth: ~+14%-+15%
🔹 Adj. Gross Margin: 68.7%-69.3%
🔹 Adj. Opex Growth: +11%-+13%
Revenue Breakdown:
🔹 Instruments & Accessories: $1.80B; +18% YoY
🔹 Systems: $769M; +30% YoY
🔹 Services: $482.2M
Procedures:
🔹 Worldwide: ~+15% YoY
🔹 da Vinci: ~+14% YoY
🔹 Ion: ~+31% YoY
System Placements:
🔹 da Vinci: 546; +28% YoY
🔹 da Vinci 5: 315; +31% YoY
🔹 Ion: 56; +12% YoY
Other Q3 Metrics:
🔹 da Vinci Installed Base: 12,094; +12% YoY
🔹 Ion Installed Base: 1,152; +21% YoY
🔹 Adj. Oper Income: $1.27B (Est. $1.13B) 🟢
Key Updates:
🔹 Antitrust settlement charge: $450M; $347M net of tax, $0.99/share
🔹 IEEPA tariff refund benefit: $22M net of tax, $0.06/share; in GAAP and non-GAAP
🔹 Expects da Vinci procedure growth closer to the midpoint of the range
🔹 Share Repurchases: $2.94B; 7.8M shares
🔹 Cash, cash equivalents, and investments: $6.80B
Comments:
🔸 “Our strong performance this quarter was marked by broad-based adoption across our multi-port, single-port, and Ion platforms, with customers using our systems to perform, on average, over 10,000 procedures per day throughout the period.”
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
5838190c88· 2026-10-21 05:10 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前